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A recently developed anti-KIR2DL5 (CD158f) antibody has demonstrated KIR2DL5 expres-
sion on the surface of NK andT lymphocytes, making it the last functional KIR identified in
the human genome. KIR2DL5 belongs to an ancestral lineage of KIR with Ig-like domains
of the D0-D2 type, of which KIR2DL4, an HLA-G receptor, is the only other human mem-
ber. Despite KIR2DL4 and KIR2DL5 being encoded by genes with similar domain usage,
several KIR2DL5 functions resemble more closely those of KIR recognizing classical HLA
class I molecules – surface-expressed KIR2DL5 inhibits NK cells through the SHP-2 phos-
phatase and displays a clonal distribution on NK andT lymphocytes. No activating homolog
of KIR2DL5 has been described in any species.The genetics of KIR2DL5 is complicated by
duplication of its gene in an ancestor of modern humans living∼1.7 million years ago. Both
KIR2DL5 paralogs have undergone allelic diversification; the centromeric gene is most
often represented by alleles whose expression is silenced epigenetically through DNA
methylation, thus providing a natural system to investigate the regulation of KIR transcrip-
tion. The role of KIR2DL5 in immunity is not completely understood, in spite of different
attempts to define its ligand. Here we revisit the most relevant characteristics of KIR2DL5,
an NK-cell receptor possessing a unique combination of genetic, structural, and functional
features.
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INTRODUCTION
KIR2DL5 (CD158f) is the most recently described human KIR
expressed on NK and T lymphocytes (Estefanía et al., 2007), for
which no ligands have yet been identified. It belongs to an ances-
tral lineage of KIR with Ig-like domains of the D0-D2 type, whose
only other member is KIR2DL4, an HLA-G receptor (Rajagopalan,
2010; Rajagopalan and Long, 2012). Although the KIR2DL5 and
KIR2DL4 genes encode proteins with a similar domain organiza-
tion, distinct structural features make several KIR2DL5 functions
resemble more closely those of KIR recognizing classical HLA class
I molecules (Table 1).
The 9.3-kbp KIR2DL5 gene was identified in 2000 by amplifi-
cation of genomic DNA with oligonucleotide primers recognizing
conserved KIR regions (Vilches et al., 2000b) and analysis of
the first sequenced KIR haplotype (Wilson et al., 2000). Exon-
walking and RACE strategies isolated the complete KIR2DL5 cod-
ing region, an open reading frame of 1128 bp encompassing eight
exons organized similarly to those of KIR2DL4 – they both lack
the fourth exon coding for the D1 Ig-like domain in all other KIR,
and encode cytoplasmic tails 20–39 amino acids longer than other
human inhibitory KIR (Vilches and Parham, 2002).
This structure is conserved in KIR2DL5 orthologs identified
in common and pigmy chimpanzees, gorillas, and orangutans
(Khakoo et al., 2000; Rajalingam et al., 2004; Guethlein et al., 2012).
Genomic and complementary DNA clones isolated from other Old
World primates resemble human KIR2DL5 in part of its sequence
or in the domain organization, but true functional orthologs
appear to be restricted to hominoids (Hershberger et al., 2001,
2005; Sambrook et al., 2005; Bimber et al., 2008; Abi-Rached et al.,
2010; Palacios et al., 2011). No activating homolog of KIR2DL5 has
been described in any species, human KIR2DS5 being homologous
to HLA-C-specific KIR.
GENETIC ORGANIZATION: TWO KIR2DL5 GENES SUBJECTED
TO EXTENSIVE COPY NUMBER VARIATION
KIR2DL5 is highly polymorphic, like other KIR, and it epitomizes
the copy number variation that is a hallmark of the KIR complex.
Non-mendelian inheritance and different relative locations of the
two most common variants seen in Caucasoids demonstrated that
KIR2DL5 alleles belong to two series encoded by different loci
(Vilches et al.,2000a; Gómez-Lozano et al.,2002). These loci,desig-
nated officially KIR2DL5A and KIR2DL5B, are now often referred
to with the suffixes T and C, for their location in the telomeric and
the centromeric intervals of the KIR complex, respectively (Marsh
et al., 2003; Pyo et al., 2010; Parham et al., 2012).
LINKAGE TO KIR2DS3S5 IN KIR -B HAPLOTYPES
Both the centromeric and the telomeric KIR2DL5 loci are fol-
lowed by the paralogs of a duplicated KIR2DS3S5 gene, each of
which encodes different alleles of the activating KIR 2DS3 and
2DS5, now considered allotypes of each other (Ordóñez et al.,
2008; Hou et al., 2010; Pyo et al., 2010). Thus, the centromeric
www.frontiersin.org September 2012 | Volume 3 | Article 289 | 1
Cisneros et al. Biology of KIR2DL5
Table 1 | Structural, genetic, and functional features of KIR2DL5 in comparison with other human KIR.
KIR2DL5 KIR2DL4 KIR2DL1 KIR3DL1
Ig-like domains D0-D2 D0-D2 D1-D2 D0-D1-D2
No. of exons encoding Ig-like domains 2 2 2+ pseudoexon 3
Charged residue in transmembrane No Yes No No
Tyrosine-based signaling motifs 1 ITIM, 1 ITSM 1 ITIM 2 ITIM 2 ITIM
Signaling molecules SHP-2>1 FcεRγ, DNA-PKcs* SHP-1>2 SHP-1>2
Function Inhibition IFNγ secretion, inhibition? Inhibition Inhibition
Transcription in NK cells Clonal Ubiquitous Clonal Clonal
Ligand Unknown HLA-G HLA-C HLA-A/B
Copy number variation ++ ± + ±**
Conservation in primates ++ +++ − ±
*(Kikuchi-Maki et al., 2005; Rajagopalan, 2010).
**Most haplotypes lacking KIR3DL1 have its KIR3DS1 allotype.
and the telomeric parts of many KIR-B haplotypes are marked
by different KIR2DL5-KIR2DS3S5 clusters (Figure 1). The com-
mon centromeric sequence KIR2DL5B∗002 is associated with
KIR2DS3∗001, whereas other KIR2DL5B alleles (see below) tend
to associate in Black populations with several KIR2DS5 alle-
les (Hou et al., 2010). On the telomeric side, the predominant
KIR2DL5A alleles, ∗001, and ∗005, are linked with KIR2DS5∗002
and KIR2DS3∗002, respectively. At its 5’ end, KIR2DL5B is nor-
mally flanked by KIR2DL2, whereas KIR2DL5A is preceded by
KIR3DS1 (Vilches et al., 2000a; Pyo et al., 2010).
DUPLICATION OF KIR2DL5 IS SPECIFIC TO HUMANS
The KIR2DL5 duplication has not been seen in other primates,
and is possibly specific to humans. Pyo et al. (2010) estimated
that an ancestral KIR2DL5-KIR2DS3S5 group duplicated ca. 1.7
million years ago, and proposed several models for subsequent
diversification through point mutation and recombination. The
duplication, seen in all races, is now fixed in our species. However,
not every human carries two (or one) KIR2DL5-KIR2DS3S5 clus-
ters, because each is subjected to presence/absence variation, with
all A haplotypes and one centromeric B haplotype lacking these
genes (Figure 1).
EXPANDED AND CONTRACTED KIR HAPLOTYPES GENERATED BY
RECOMBINATION IN THE KIR2DL5-KIR2DS3S5 CLUSTER
On the other hand, presence of two highly homologous sequence
segments in two different parts of the KIR complex has facilitated
subsequent asymmetric (i.e., non-allelic) homologous recombi-
nation resulting in contracted and expanded haplotypes (one of
them with a third KIR2DL5 locus), often carrying fusion genes
or alleles, as represented in Figure 1 (Gómez-Lozano et al., 2003,
2005, 2007; Martin et al., 2003; Ordóñez et al., 2008, 2011; Hou
et al., 2012). In contracted haplotypes lacking the central frame-
work KIR genes, assignment of KIR2DL5 and KIR2DS3S5 to the
centromeric or the telomeric sides is somewhat arbitrary.
KIR2DL5 ALLELIC POLYMORPHISM
THE KIR2DL5 CODING REGION
KIR2DL5 is represented in the Immuno Polymorphism Database
(v2.4.0) by 15 KIR2DL5A and 25 KIR2DL5B alleles (Robinson
et al., 2010). Nineteen polymorphic sites have been found within
the 1125-bp coding region, of which 11 are non-synonymous.
Twelve nucleotide substitutions occurring in exons 3 and 5 create
seven amino acid replacements in the extracellular Ig-like domains
(Table 2), which may reflect balancing selection having favored
polymorphisms that could modulate avidity or specificity in the
interaction of KIR2DL5 with unknown ligands. Du et al. (2008)
pointed out, however, that many polymorphisms fall out of pre-
dicted ligand-interacting loops of the Ig-like domains. Of note, a
single polymorphism in exon 1 distinguishes all KIR2DL5A from
all KIR2DL5B alleles, whilst many substitutions are shared by alle-
les of both loci (Table 2). An extensive exchange of genetic material
between the centromeric and the telomeric KIR2DL5 loci has taken
place during human evolution, as eloquently illustrated by two
allele pairs (one from each locus) and a four-allele group (two from
each locus) encoding identical mature polypeptides and differing
only in their signal peptides. Among 65 additional polymorphisms
occurring in KIR2DL5 introns (not shown), none alters its splicing
sites.
POLYMORPHISM IN THE KIR2DL5 PROXIMAL PROMOTER REGION
The regulatory regions upstream of the KIR2DL5 genes are
even more polymorphic – the three first known KIR2DL5 alle-
les are distinguished by 20–32 nucleotide substitutions in the
1.2-Kbp region immediately 5′ of their start codon (1.6–2.5%
variation). A neighbor-joining phylogenetic tree based on the
nucleotide sequences of this region sorts KIR2DL5 alleles into
three well-differentiated lineages. One of them includes all and
only KIR2DL5A alleles; a second lineage comprises multiple
KIR2DL5B alleles, of which 2DL5B∗0020101 is the prototype; and
the third cluster is formed by KIR2DL5B∗003 and ∗00602 (Du
et al., 2008). We will refer herein to these clusters as promoters
of types I, II, and III. The origin of this divergence, of profound
functional importance (alleles controlled by type II promoter are
not transcribed), has not been explained.
DISTRIBUTION OF KIR2DL5 ALLELES
KIR2DL5 is present in all human populations at frequencies
ranging from 26 to 86%, but the distributions of the two par-
alogs and their allotypes are uneven. Whereas KIR2DL5A and
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FIGURE 1 | Copy number variation and allelic polymorphism of KIR2DL5-KIR2DS3S5 clusters contribute substantial diversity to KIR haplotypes.
KIR2DL5B predominate in Mongoloid and Black populations,
respectively, they have similar frequencies in Caucasoids. Alleles
KIR2DL5A∗001, B∗002, and A∗005 are widely distributed, accom-
panied by B∗006 in Blacks, who retain the highest KIR2DL5
diversity, and constitute the only human group in which KIR2DL5
alleles controlled by the third type of promoter are not rare
(Vilches et al., 2000a; Gómez-Lozano et al., 2007; Du et al., 2008;
Middleton et al., 2008; Mulrooney et al., 2008; Hou et al., 2010;
González-Galarza et al., 2011 and our own unpublished results).
KIR2DL5 AND DISEASE
Data on possible implication of KIR2DL5 copy number varia-
tion and polymorphism in susceptibility to disease are scarce.
Complex polymorphism and strong linkage disequilibrium with
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Table 2 | Comparison of the deduced primary structures and surface expression profiles of KIR2DL5 alleles.












−16 Ile −1Thr 16 Ala 78 His 95 Val 114 Arg 152 Asn 167 Gly 174 Gly 215 Arg 284 Val
A*001 – – – – – – – – – – – Yes
B*008 Val – – – – – – – – – – na
A*012 – Pro – – – – – – – – – (Yes)
B*006 Val Pro – – – – – – – – – (Yes)/na
A*015 – – – – – Cys – – – – – ?
B*013 Val – – – – Cys – – – – – na
A*005 – – – – – – Asp – Ser – – No
B*002 Val – – – – – Asp – Ser – – na
A*014 – – – – – – – Arg – – – ?
B*004 Val – Thr – – – – – – – – na
B*007 Val – – – Met – – – – – – na
B*003 Val Pro – – Met – – – – – – ?
B*011 Val Pro – – – – – – – – Ile na
B*009 Val – – – – – Asp – Ser Leu – na
B*010 Val Pro – – – – Asp – Ser – – na
B*016 Val – – Tyr – – Asp – Ser – – na
*Yes: surface expression demonstrated by flow cytometry with UP-R1; No: lack of staining with UP-R1 demonstrated in KIR2DL5A*005 cells; (Yes): surface expression
and staining with UP-R1 is predictable, according to the allele primary structure and promoter type, but has not been assessed; ?: surface expression and staining
with UP-R1 can not be predicted in a transcribed allele, due to polymorphisms in the ectodomain; na: not applicable due to demonstrated or likely lack of transcription;
(Yes)/na: different variants of allele KIR2DL5B*006 have functional or non-functional promoters (Table 3). KIR2DL5A alleles are shown in blue, and KIR2DL5B ones,
in green. Allele order has been arranged to highlight patterns of homology between alleles.
neighboring KIR genes complicates evaluating the individual role
of KIR2DL5 as a risk or a protective factor. Search of the PubMed
database with the term “KIR2DL5” in June 2012 retrieved 16
citations describing significant deviations of the gene frequency
in different diseases and clinical situations (not shown). Among
them, only an association between ankylosing spondylitis and
presence of KIR2DL5 in the genome of Asian patients has been
replicated (Díaz-Peña et al., 2008; Jiao et al., 2008, 2010).
KIR2DL5 GENOTYPING
KIR2DL5 polymorphism has been explored using PCR
with sequence-specific primers (SSP) or oligonucleotide-probe
hybridization (2008), methods that reliably identify common
alleles (Gómez-Lozano and Vilches, 2002; Gómez-Lozano et al.,
2007; González et al., 2008). Sequence-based typing (SBT) and
mass spectrometry methods that enable studying the entire
KIR2DL5 sequence have led to identification of multiple new alle-
les (Houtchens et al., 2007; Du et al., 2008; Mulrooney et al.,
2008; Hou et al., 2010). However, existence of two KIR2DL5
loci poses extra difficulties to genotyping: firstly, because a per-
son having the two loci on both chromosomes may have up to
four different KIR2DL5 sequences; secondly, because the alleles of
each locus share many single-nucleotide polymorphisms (SNPs).
Knowing the phase of KIR2DL5 SNPs is essential for locus/allele
assignment, but this is hindered by the hundreds or thousands
of base-pairs separating many individual polymorphism (e.g., the
only locus-specific SNP in exon 1 is ca. 3 Kbp apart from those in
exon 5). The published methods can make tentative assignments
of reasonable reliability on samples derived from populations in
which the KIR2DL5 allele distribution has been previously inves-
tigated in depth, but none of them can assign unambiguously
all possible KIR2DL5 genotypes. Separation of KIR2DL5 alleles
by locus-specific long-range PCR, followed by probe hybridiza-
tion or enzymatic sequencing, and long reads of individual DNA
molecules by second-generation sequencing are promising strate-




The fact that highly similar KIR2DL5 coding sequences are con-
trolled by three structurally divergent forms of promoter has
profound functional consequences, constituting a valuable nat-
ural experiment that provides major insight into the complex
regulation of KIR transcription. Of the KIR2DL5 alleles whose
transcription has been investigated, those controlled by type I
or type III promoters feature variegated patterns of expression;
whilst mRNA of alleles controlled by type II promoters is unde-
tectable (Vilches et al., 2000a; Gómez-Lozano et al., 2007). No
single exception to this rule has ever been described; further-
more, the KIR3DP1 pseudogene, also controlled by a type II
promoter, is transcriptionally silent too, with a key exception:
as the empirical rule predicted, KIR3DP1∗004, which gained
a type I promoter through recombination with KIR2DL5A, is
an expressed allele (Vilches et al., 2000b; Gómez-Lozano et al.,
2005).
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Consistent with the epigenetic regulation of KIR genes (San-
tourlidis et al., 2002; Chan et al., 2003), lack of transcription of
the silent KIR2DL5B∗002 allele correlates with a hypermethylated
status of CpG islands in its promoter. Furthermore, pharmacolog-
ical DNA demethylation of cultured NK cells suffices for restoring
KIR2DL5B∗002 transcription, demonstrating that only an epige-
netic mechanism prevents its expression (Gómez-Lozano et al.,
2007). In agreement with this are studies of transiently transfected
promoters controlling a reporter gene, an in vitro situation in
which epigenetic regulation is not relevant. In this setting, the
promoters of naturally silent KIR2DL5 alleles tend to show simi-
lar or higher activities than functional KIR alleles (Gómez-Lozano
et al., 2007; Mulrooney et al., 2008).
Among the sequence patterns that distinguish the three types of
KIR2DL5 promoter, only two linked SNPs at nucleotides 97 and 84
upstream of the start codon correlate completely with the expres-
sion pattern: GA is seen in transcribed alleles, and AG in silent
ones (Table 3). Nucleotide −97G lies within a TGTGGT motif
that provides a core binding site for the RUNX family of tran-
scription factors (Vilches et al., 2000a). RUNX3 is recruited from
nuclear extracts of NK cells by probes derived from KIR2DL5 alle-
les having an intact motif, but not by those carrying the−97G>A
mutation (Gómez-Lozano et al., 2007). In support of an essential
role for RUNX in KIR expression is conservation of its binding
motif in all human KIR with clonal transcription (Trompeter et al.,
2005; van Bergen et al., 2005; Presnell et al., 2006); and demon-
stration that two redundant RUNX binding sites, highly conserved
in primates, are possibly essential for expression of KIR2DL4, a
gene that is transcribed ubiquitously in NK cells (Presnell et al.,
2012).
KIR transcription is controlled not only by a proximal pro-
moter, but also by the complex interaction of additional regulatory
elements (Cichocki et al., 2011). In brief, a distal, non-tissue-
specific promoter element located ∼1.1 Kbp upstream of the KIR
start codon has been suggested to induce histone modifications
that facilitate subsequent function of the proximal promoter. The
latter is actually bidirectional – reverse transcripts derived from
it have been proposed to repress KIR expression and favor epi-
genetic silencing, whilst predominance of forward transcription
would result in KIR expression. Finally, an additional reverse pro-
moter element in intron 2 appears to function in early NK-cell
progenitors. It has been suggested that the RUNX role might be
to down-regulate the antisense promoter activity during NK-cell
ontogeny, thus favoring a local open chromatin conformation at
the bound KIR gene, and its subsequent expression in the mature
cell (Davies et al., 2007; Cichocki et al., 2011). Consistent with
this hypothesis is that the only reverse KIR transcripts detected in
CD56bright NK cells (possible precursors of KIR+CD56dim cells)
are those derived from genes with promoters lacking the RUNX
binding site – KIR2DL5B∗002 and KIR3DP1 (Davies et al., 2007).
Other locus- and allele-specific polymorphisms of these reg-
ulatory elements influence KIR transcription and may also help
us understand mechanisms controlling KIR2DL5 expression. For
instance, a Ying Yang-1 (YY1) binding site conserved in many
proximal KIR promoters is mutated in KIR 2DL1, 2DS1/S3/S5, and
all KIR2DL5 alleles, which correlates with enhanced reverse tran-
scription (Davies et al., 2007; Li et al., 2008). This phenomenon
may induce low forward activity of the KIR2DL5 promoter, which
might be associated with the receptor being generally expressed
at low levels on the surface of only small proportions of NK cells
(Estefanía et al., 2007). Likewise, disruption of the Sp1 site in
the promoter of the expressed allele KIR2DL5B∗003 (−27C>T,
Table 3) decreases its forward activity in vitro and has been pro-
posed to reduce its expression on NK cells (Li et al., 2008), which
needs experimental confirmation.
Of possible interest, none of the transcriptionally silent
KIR2DL5B alleles bear structural abnormalities in their reading
frames (in contrast with other human KIR, no null KIR2DL5 alle-
les have yet been identified; Vilches et al., 2000a; Robinson et al.,
2010). The fact that KIR2DL5B generally retains an intact struc-
ture could mean that inactivation of its expression is evolutionarily
recent (the mutated RUNX site is not seen in other hominoids, per-
sonal communication of Libby Guethlein, Stanford University); or
that the gene still serves an unknown function.
Table 3 | Comparison of the proximal promoter sequences and transcription profiles of KIR2DL5 alleles.
KIR2DL5 allele Promoter region Promoter type Transcription
−104 G −97 G −84 A −27 C −23 C −10 C
A*0010101–00105 – – – – – – I +
A*0050101/03–04 – – – – – – I +
A*01201/02 – – – – – – I (+)
A*0050102 A – – – – – I (+)
B*0020101–03/05/07, *0070101 A A G – T – II −
B*004, *0080101/00802, *009, *01301/02 A A G – T – II −
B*00601/03 A A G – – – II −
B*0020104, *00202, *0080102, *010, *011 A A G – – – II (−)
B*003 A – – T – T III +
B*00602 A – – T – T III (+)
Transcription of the alleles shown in bold face has been assessed experimentally; in parentheses are shown predictions for groups of alleles of which no member
has been studied by RT-PCR. The promoter regions of KIR2DL5 alleles A*014, A*015, B*0020106, B*0070102, B*01303, and B*016 have not been sequenced.
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CELL SURFACE EXPRESSION
Generation of a specific monoclonal antibody (clone UP-R1)
enabled us to characterize KIR2DL5 surface expression (Estefanía
et al., 2007). Like most other KIR (and contrasting with the non-
clonal expression of KIR2DL4), KIR2DL5 features a variegated
pattern on the surface of CD56dim NK cells and on T lymphocytes
from peripheral blood, in agreement with the clonal distribution
seen by reverse transcription (RT) PCR in mRNAs isolated from
NK- and T-cell clones (Vilches et al., 2000b; Estefanía et al., 2007).
The proportion of NK cells expressing KIR2DL5 tends to be lower
than 10% in most healthy individuals. That proportion is even
lower in T lymphocytes, of the CD8 subset in their vast majority.
The receptor density on the surface, as assessed by the median
fluorescence intensity (MFI) value in flow cytometry with mAb
UP-R1, is also lower than for several other KIR in resting lym-
phocytes, but it increases, to a lesser extent, upon expansion in
presence of IL-2 and lymphoblastoid cell lines (our own observa-
tion). These features might owe to weak promoters controlling the
transcription of functional KIR2DL5 alleles.
Interestingly, higher numbers of KIR2DL5+ cells (20% of total
NK lymphocytes) have been reported in a TAP-deficient woman.
Furthermore, the phenotype of this patient also differed from that
of most TAP-deficient individuals in her resting NK cells retaining
cytotoxic capacity against allogeneic targets without pre-activation
(Zimmer et al., 2009). The exact mechanisms determining this
behavior remain to be ascertained.
Analysis of bulk and cloned NK cells by flow cytometry and
RT-PCR reveals no coordinated expression of KIR2DL5 with other
KIR, but rather an apparently random distribution (Vilches et al.,
2000b; Estefanía et al., 2007). Importantly, a minority of NK cells
expresses KIR2DL5 but neither other inhibitory KIR, nor the
inhibitory lectin-like receptor NKG2A. Existence of this subpop-
ulation is consistent with a capacity of KIR2DL5 to license NK
cells, but this has not been demonstrated functionally. Also lack-
ing are studies on possible patterns of co-expression of KIR2DL5
and LILRB1, the third lineage of inhibitory MHC class I receptors
expressed by human NK cells.
Allelic polymorphism is essential for understanding the dif-
ferent patterns of KIR2DL5 expression (Table 2). Transcription-
ally silent alleles are, obviously, undetectable on the cell sur-
face by definition. Furthermore, only allele KIR2DL5A∗001 has
been formally demonstrated to be expressed on the cell surface.
In contrast, NK cells transcribing allele KIR2DL5A∗005 are not
stained by mAb UP-R1 in flow cytometry (Gómez-Lozano et al.,
2007). Whether this is due to a lack of surface expression, to
the UP-R1 epitope being altered in KIR2DL5A∗005 by its D2-
domain polymorphisms, or to a combination of both factors,
has not yet been elucidated. Surface expression and recognition
by UP-R1 of other transcribed KIR2DL5 alleles has, to the best
of our knowledge, never been evaluated. Amongst other tran-
scriptionally active KIR2DL5 alleles, A∗012 and B∗00602 code
for mature polypeptides identical to A∗001, therefore they are
predictably surface-expressed and detected by UP-R1; whereas
expression and UP-R1 recognition of KIR2DL5B∗003, A∗014, and
A∗15 (each bearing one amino acid replacement in the Ig-like
domains in comparison with A∗001) needs to be tested empirically
(Table 2).
KIR2DL5 FUNCTION
KIR2DL5 INHIBITS NK CELLS
KIR2DL5 is predominantly expressed on the cell surface as a
glycosylated monomer of∼60 kDa (Estefanía et al., 2007). Its cyto-
plasmic tail contains one canonical (VxYxxL) immunoreceptor
tyrosine-based inhibitory motif (ITIM) separated by 24 amino
acid residues from an atypical ITIM sequence (TxYxxL) simi-
lar to the immunoreceptor tyrosine-based switch motifs (ITSM)
seen in 2B4, SLAM, and other receptors (Vilches et al., 2000b;
Yusa et al., 2004). The latter motif, not seen in other human KIR,
does not confer upon KIR2DL5 the capacity to recruit and signal
through the SLAM-associated protein (SAP), but it is conserved in
KIR2DL5 orthologs of other hominoids (Rajalingam et al., 2004;
Yusa et al., 2004).
Since the KIR2DL5 ligand is unknown, its actual inhibitory
character in physiological conditions has not been explored. Cross-
linkage of naturally expressed KIR2DL5 inhibits NK-cell cytotoxi-
city against mAb-coated P815 target cells to an extent comparable
to that seen with the “classical” KIR 3DL1 (Estefanía et al., 2007).
This result is in agreement with that obtained previously using
NK92 cells transduced with a chimera containing a KIR3DL1
ectodomain fused to the KIR2DL5 cytoplasmic tail; such chimera,
however, displayed a lower capacity to inhibit NK92-target conju-
gation than full-length KIR3DL1 (Yusa et al., 2004). Based on the
results obtained with a mutated KIR3DL1/2DL5 chimera, Yusa
et al. (2004) proposed that the canonical KIR2DL5 ITIM, but
not its ITSM-like motif, is essential for its inhibitory capacity in
transduced NK92 cells.
Experiments performed independently on transduced NK92
cells and on NK cells expressing endogenous KIR2DL5 demon-
strated that the phosphorylated receptor recruits the Src homology
region 2-containing protein tyrosine phosphatase 2 (SHP-2) pref-
erentially over SHP-1 in comparison with other KIR (Yusa et al.,
2004; Estefanía et al., 2007). Furthermore, the inhibitory effect of
the KIR2DL5 tail in transduced NK92 cells was prevented by a
dominant-negative (DN) SHP-2, but only to a lesser extent by DN
SHP-1 (Yusa et al., 2004). The importance of KIR2DL5 using pre-
dominantly a SHP-2-dependent pathway for its function has not
been explored in depth.
KIR2DL5, AN ORPHAN RECEPTOR
Demonstration that KIR2DL5 is a surface-expressed glycoprotein
capable of inhibiting cytotoxic lymphocytes suggested that this
molecule participated in NK-cell mediated defense according to
the missing-self model. Such a possibility was reinforced by iden-
tification of NK cells which express KIR2DL5 and lack all other
detectable inhibitory KIR and NKG2A, and it implies existence of
a cellular ligand, possibly expressed in physiological conditions.
Enhanced KIR2DL5 expression and retention of NK-cell cytotox-
icity in a TAP-deficient patient (Zimmer et al., 2009) suggest that
she possibly expressed a ligand capable of licensing KIR2DL5+NK
cells.
As a first approach to investigate expression of a KIR2DL5
ligand, we made a fusion protein containing the KIR2DL5
ectodomains and the Fc of human IgG1. The fusion protein, along
with positive and negative controls (KIR2DL1-, KIR2DL2-, and
non-fused Fc constructs kindly donated by Dr. Eric Long), was
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produced in human embryonic kidney (HEK)-293T cells, and
used in indirect flow cytometry experiments on multiple cell lines
grown in vitro. In these experiments, we observed a dull stain-
ing of, essentially, every human cell line of hematopoietic origin.
Such staining seemed independent of the cells HLA allotypes; fur-
thermore, it was apparently not affected by lack of surface HLA
expression in mutant cell lines (results not shown). However, the
variably low signal-to-noise ratios with which the positive controls
often stained cells expressing their known ligands, and the variable
behavior of different batches of fusion proteins of known speci-
ficity indicated that the method did not attain sufficient sensitivity
and consistency in our hands to allow screening for an unknown
ligand in a series of heterogeneous cell types.
As an alternative approach of possibly higher sensitivity, we
tried to apply the MHC-tetramer technology to build KIR2DL5
forms of higher avidity. The first codons of a KIR2DL5 cDNA
were adapted by site-directed mutagenesis to the codon usage
bias of Escherichia coli (Nakamura et al., 2000), for higher pro-
tein yield; and the construct encoding the Ig-like and stem
regions of KIR2DL5 was subcloned into the pGMT7 plas-
mid (a kind gift of Dr. Veronique Braud), which provided
an in-frame recognition sequence for the BirA biotinylase at
the carboxy-terminal end of the construct. Upon IPTG induc-
tion, the recombinant KIR2DL5 protein was efficaciously pro-
duced in strain BL21(DE3)pLysS. After purification from inclu-
sion bodies, the KIR2DL5 ectodomain was solubilized in con-
centrated urea, refolded in an arginine/gluthation buffer, and
biotinylated with BirA. However, the labeled KIR2DL5 pro-
tein could not be quantitatively recovered after molecular
exclusion chromatography, apparently due to aggregation, even
in presence of mild detergents like Chaps and Octyl-b-d-
glycopyranoside.
The ability to identify KIR2DL5 with a novel specific mon-
oclonal antibody opened new possibilities for studying the out-
come of the interaction of KIR2DL5-positive NK lymphocytes
with potential target cells. For instance, we attempted to study
differential degranulation (assessed by CD107a expression) of
KIR2DL5-positive and -negative NK cells against different target
cells. However, several hindrances made this approach unpractical,
including: low levels of degranulation induced in freshly isolated
NK cells by many targets, which made it difficult to evaluate any
further reduction attributable to inhibition through KIR2DL5; the
low proportions of NK cells expressing KIR2DL5 in most donors,
which do not readily increase during in vitro NK-cell expansion in
response to lymphoblastoid cell lines. These studies indicated that
use of cells homogeneously expressing KIR2DL5, and of a posi-
tive readout (rather than inhibition of another signal) are more
promising approaches for screening the interaction of KIR2DL5
with potential ligand molecules. Knowing such interactions is
essential for understanding the role of KIR2DL5 in immunity,
and its importance for human health.
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